ImageneBio (IMA)
NASDAQ:IMA
Want to see IMA full AI Analyst Report?
Top Page
ImageneBio
(NASDAQ:IMA)
Select Model
Select Model
Rating:48Neutral
Price Target:
$5.00
▼(-15.25% Downside)
Action:Reiterated
Date:05/09/26
IMA scores low-to-mid primarily due to minimal current revenue, sizable ongoing losses, and sustained cash burn that create continued funding risk. The score is supported by a low-debt balance sheet and the recent ~$30M financing that improves liquidity, but technicals remain weak with the stock trading below key moving averages and valuation metrics are not meaningful given losses.
Positive Factors
Low leverage / strong balance sheet
Very low debt provides durable financial flexibility for a pre-commercial biotech: it lowers fixed financing costs and bankruptcy risk, enabling management to prioritize funding clinical programs and R&D rather than servicing debt, which supports sustained pipeline progress.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow of roughly -$52M TTM is a durable constraint: the company must repeatedly access capital markets to fund operations, which raises dilution risk and could delay or reduce pipeline investment if markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low debt provides durable financial flexibility for a pre-commercial biotech: it lowers fixed financing costs and bankruptcy risk, enabling management to prioritize funding clinical programs and R&D rather than servicing debt, which supports sustained pipeline progress.
Read all positive factors
ImageneBio (IMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$63.20M
Dividend YieldN/A
Average Volume (3M)69.52K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue GrowthN/A
EPS Growth49.30%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,654,281
10 Day Avg. Volume58,561
30 Day Avg. Volume69,515
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.25
Price to Sales (P/S)42.01
P/FCF Ratio-0.70
Enterprise Value/Market Cap-0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.14
Enterprise Value/Ebitda0.16
Forecast
1Y Price Target
$13.00Price Target Upside120.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ImageneBio Business Overview & Revenue Model
Company Description
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis...
How the Company Makes Money
null...
ImageneBio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 800.00K | 3.50M | 9.16M | 15.62M | 30.98M |
| Gross Profit | -780.00K | -233.00K | 3.50M | 8.14M | -48.70M | -16.12M |
| EBITDA | -53.13M | -47.42M | -35.47M | -74.40M | -70.15M | -33.59M |
| Net Income | -45.07M | -45.35M | -36.57M | -68.17M | -68.77M | -34.12M |
Balance Sheet | ||||||
| Total Assets | 136.68M | 152.98M | 141.51M | 192.09M | 172.26M | 247.88M |
| Cash, Cash Equivalents and Short-Term Investments | 117.21M | 75.78M | 124.39M | 175.47M | 156.95M | 232.22M |
| Total Debt | 8.15M | 9.99M | 7.52M | 10.74M | 5.69M | 6.99M |
| Total Liabilities | 13.36M | 19.84M | 15.58M | 22.34M | 25.29M | 40.00M |
| Stockholders Equity | 123.33M | 133.14M | 125.93M | 169.76M | 146.97M | 207.88M |
Cash Flow | ||||||
| Free Cash Flow | -52.08M | -47.84M | -46.00M | -80.16M | -75.54M | -62.01M |
| Operating Cash Flow | -52.08M | -47.84M | -46.00M | -79.74M | -74.11M | -60.25M |
| Investing Cash Flow | -14.19M | -5.81M | -34.90M | 64.14M | -99.28M | -1.76M |
| Financing Cash Flow | 132.22M | 135.47M | 0.00 | 75.98M | 1.09M | 131.74M |
ImageneBio Technical Analysis
Negative
5.90
Price Trends
5.60
Negative
6.18
Negative
7.69
Negative
Market Momentum
-0.03
Positive
41.64
Neutral
42.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMA, the sentiment is Negative. The current price of 5.9 is above the 20-day moving average (MA) of 5.76, above the 50-day MA of 5.60, and below the 200-day MA of 7.69, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 41.64 is Neutral, neither overbought nor oversold. The STOCH value of 42.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMA.
ImageneBio Risk Analysis
ImageneBio disclosed 73 risk factors in its most recent earnings report. ImageneBio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ImageneBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $269.13M | -1.52 | -124.06% | ― | ― | 39.66% | |
53 Neutral | $160.64M | -4.32 | -48.20% | ― | 7336.90% | 49.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $158.83M | -2.57 | -220.75% | ― | ― | 38.59% | |
49 Neutral | $84.29M | -90.96 | -57.20% | ― | -1.10% | -135.24% | |
48 Neutral | $63.20M | -1.32 | -35.20% | ― | ― | 49.30% | |
44 Neutral | $73.07M | -0.97 | -59.06% | ― | ― | 49.00% |
* Healthcare Sector Average
IMA
ImageneBio
5.25
-8.55
-61.96%
IMUX
Immunic
11.60
2.40
26.09%
CSBR
Champions Oncology
5.98
0.00
0.00%
PLRX
Pliant Therapeutics
1.15
-0.18
-13.53%
ALXO
ALX Oncology Holdings
1.96
1.55
378.05%
ADAG
Adagene
3.40
1.74
104.82%
ImageneBio Corporate Events
Business Operations and StrategyPrivate Placements and Financing
ImageneBio Announces $30 Million Private Warrant Financing
Positive
Apr 13, 2026
On April 12, 2026, ImageneBio, Inc. entered into a Securities Purchase Agreement with institutional and accredited investors for a private placement of pre-funded warrants to purchase up to 5,770,335 shares of common stock at $5.199 per warrant sh...
Executive/Board Changes
ImageneBio Announces Leadership Transition in Finance Organization
Neutral
Mar 17, 2026
On March 12, 2026, ImageneBio, Inc. agreed to a mutual separation with Erin Butler, its Senior Vice President, Finance Administration and Principal Accounting Officer, effective March 20, 2026, with Butler expected to receive severance benefits u...
Executive/Board Changes
ImageneBio announces immediate resignation of board director
Neutral
Feb 17, 2026
On February 12, 2026, ImageneBio, Inc. announced that Steven Hui Wang resigned from its Board of Directors, effective immediately. The company stated that Wang’s departure did not arise from any disagreement regarding ImageneBio’s oper...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.